Cell-based hepatitis C virus infection fluorescence resonance energy transfer (FRET) assay for antiviral compound screening.
Cell-based hepatitis C virus infection fluorescence resonance energy transfer (FRET) assay for antiviral compound screening.
复制标题
基于细胞的丙型肝炎病毒感染荧光共振能量转移（FRET）测定用于抗病毒化合物筛选。
DOI：
10.1002/9780471729259.mc1705s18
复制
发表时间：
2010
影响因子：
--
通讯作者：
Uprichard,SusanL
中科院分区：
文献类型：
--
作者：
Yu,Xuemei;Uprichard,SusanL
丙型肝炎病毒（HCV）影响估计3%的人口，是全球慢性肝病的主要原因。由于HCV的治疗和预防选择有限，开发新的HCV抗病毒药物已成为全球卫生保健关注的问题。这刺激了基于细胞的感染性HCV高通量筛选测定的发展，以测试化合物抑制HCV感染的能力。本单元描述了可用于使用基于细胞的高通量荧光共振能量转移（FRET）HCV感染筛查试验评估HCV抗病毒药体外疗效的方法，该试验允许在病毒生命周期的任何步骤中鉴定靶向HCV的抑制剂。提供了HCV感染期间化合物筛选和使用HCV FRET测定分析化合物功效的基本方案。提供了用于传播感染性HCV和测量病毒感染性的支持方案。方案Microbiol. 18：17.5.1 - 17.5.27。© 2010年由约翰威利父子公司。
Hepatitis C virus (HCV) affects an estimated 3% of the population and is a leading cause of chronic liver disease worldwide. Since HCV therapeutic and preventative options are limited, the development of new HCV antivirals has become a global health care concern. This has spurred the development of cell‐based infectious HCV high‐throughput screening assays to test the ability of compounds to inhibit HCV infection. This unit describes methods that may be used to assess the in vitro efficacy of HCV antivirals using a cell‐based high‐throughput fluorescence resonance energy transfer (FRET) HCV infection screening assay, which allows for the identification of inhibitors that target HCV at any step in the viral life cycle. Basic protocols are provided for compound screening during HCV infection and analysis of compound efficacy using an HCV FRET assay. Support protocols are provided for propagation of infectious HCV and measurement of viral infectivity.Curr. Protoc. Microbiol. 18:17.5.1‐17.5.27. © 2010 by John Wiley & Sons, Inc.